Tropical Journal of Pharmaceutical Research
Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria
Vol. 9, No. 5, 2010, pp. 431-439
Bioline Code: pr10051
Full paper language: English
Document type: Research Article
Document available free of charge
Tropical Journal of Pharmaceutical Research, Vol. 9, No. 5, 2010, pp. 431-439
© Copyright 2010 Tropical Journal of Pharmaceutical Research.
Angiotensin Converting Enzyme Insertion/Deletion Gene Polymorphism: An Observational Study among Diabetic Hypertensive Subjects in Malaysia|
Jayapalan, Jaime Jacqueline; Muniandy, Sekaran & Pheng, Chan Siew
Purpose: This study investigated the influence of angiotensin-1 converting enzyme (ACE) insertiondeletion
(ID) gene polymorphism on the treatment responses of type 2 diabetic subjects at varying
stages of nephropathy to ACE inhibitors (ACEI) with regard to blood pressure (MAP) and renal response
Methods: The pharmacological effect of ACE inhibition on mean arterial pressure (MAP) and glomerular
filtration rate (GFR) were observed among a total of 62 subjects for a short-term duration of 15 months.
MAP and GFR were calculated by standard mathematical formulae while the ACE ID genotype was
determined using triple primer PCR. The general linear model repeated measures were applied to study
the modulation of ACE inhibition on these parameters.
Results: ACE ID genotyping of the 62 subjects showed that 19 (30.6 %) subjects had the II genotype,
while 35 (56.4 %) subjects showed ID genotype and 8 (12.9 %) subjects had the DD genotype.
Significant mean MAP reduction (p < 0.05) and null mean GFR changes (p > 0.05) from baseline values
were observed among the subjects following antihypertensive treatment. However, when stratified
according to ACE genotypes, no significant mean MAP and GFR changes were observed between
genotypes following antihypertensive treatment (p > 0.05).
Conclusion: ACE ID gene polymorphism does not determine the treatment efficacy of ACE inhibitors in
the Malaysian population.
ACE genotype, ACE inhibitor, Type 2 diabetes mellitus, Diabetic nephropathy
Alternative site location: http://www.tjpr.org